Literature DB >> 18188813

[Changes in socio-economics, quality of life and knowledge of patients with chronic hepatitis C during the Hepatitis Competence Net Project].

C Niederau1, G Bemba, A Kautz.   

Abstract

AIMS AND METHODS: The study of the Patient Support Group Deutsche Leberhilfe e.V. and the Federal Hepatitis Competence Net prospectively analysed questionnaires about quality of life (SF12) and socio-economical data of patients with chronic hepatitis C (CHC). A 1st questionnaire 3 1/2 years ago gathered information in 714 CHC patients all of whom now received a 2nd questionnaire which was sent back by 503 subjects (71%).
RESULTS: Both mental and physical SF 12 scores remained markedly decreased compared with scores for the general population which approximate 50 points (p<0.001). When compared to values obtained 3S years ago, mental scores increased from 41.2 to 42.5 and physical scores from 41.9 to 42.9 (changes not significant by analysis of variance; p>0.05). However, in patients with negative HCV-RNA, physical and mental scores significantly increased by 6.9 and 4.0 points (p<0.01). In contrast, mental and physical scores decreased by 2.4 and 2.5 points during follow-up in patients with fibrosis (Metavir F2-4) (p<0.05). SF 12-scores closely correlated with degrees of inflammation and fibrosis (p<0.001, respectively). Quality of life was associated with socio-economical data and gradually increased with higher school graduation. A high percentage of patients with CHC were unemployed (18%); of patients aged 65 years, 25% were already retired; 60% of the retired subjects received a disability pension, 37% because of CHC. Unemployed patients had lower SF 12 scores than patients with a job. Subjects with public employers had significantly lower SF 12 scores than privately or self-employed subjects. Complications of CHC markedly reduced SF 12 scores. Just 37% of subjects had a life insurance and only 9% had an insurance of occupational invalidity (values 2-3-times lower than those in the general German population). Insurance applications for life and occupational invalidity had been denied in 17 and 53%, respectively; the denial values were even higher than in the 1st questionnaire.
CONCLUSIONS: The prospective follow-up shows that quality of life continuously improves after elimination of HCV, whereas mental and physical health get increasingly worse with ongoing fibrosis. The analysis demonstrates that many CHC subjects have severe socio-economical problems leading to unemployment, early retirement and lack of appropriate insurances. These problems further reduce the quality of life in CHC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18188813     DOI: 10.1055/s-2007-963534

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  4 in total

1.  Chronic hepatitis C: treat or wait? Medical decision making in clinical practice.

Authors:  Claus Niederau; Dietrich Hüppe; Elmar Zehnter; Bernd Möller; Renate Heyne; Stefan Christensen; Rainer Pfaff; Arno Theilmeier; Ulrich Alshuth; Stefan Mauss
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

Review 2.  Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.

Authors:  Salvatore Monaco; Sara Mariotto; Sergio Ferrari; Massimiliano Calabrese; Gianluigi Zanusso; Alberto Gajofatto; Domenico Sansonno; Franco Dammacco
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself.

Authors:  Edna Strauss; Francisco Augusto Porto-Ferreira; Cesar de Almeida-Neto; Maria Cristina Dias Teixeira
Journal:  Clin Res Hepatol Gastroenterol       Date:  2013-11-14       Impact factor: 2.947

Review 4.  Hepatitis C virus infection and the brain.

Authors:  Karin Weissenborn; Anita B Tryc; Meike Heeren; Hans Worthmann; Henning Pflugrad; Georg Berding; Martin Bokemeyer; Hans L Tillmann; Annemarie Goldbecker
Journal:  Metab Brain Dis       Date:  2009-01-07       Impact factor: 3.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.